| Comparison between three- and six-month postoperative refractive and visual results after laser epithelial keratomileusis with mitomycin C. | |
| | |
MedLine Citation:
|
PMID: 18774546 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To compare the residual refraction and visual results between the three- and six-month postoperative visits to detect the optimal moment for enhancement after myopic laser epithelial keratomileusis (LASEK) with mitomycin C (MMC). DESIGN: Nonrandomized, interventional, prospective study. METHODS: One hundred and forty-one consecutive eyes that underwent LASEK with MMC to correct their myopia using the Esiris excimer laser (Schwind Eye Tech Solutions, Kleinostheim, Germany), and that showed three months postoperatively a residual defect or a suboptimal uncorrected visual acuity (UCVA) or best spectacle-corrected visual acuity (BSCVA) were included in the study. We compared the residual spherical refraction and cylinder, the UCVA, and the BSCVA between the three- and six-month postoperative examinations. RESULTS: Preoperative spherical refraction was -5.2 +/- 2.90 diopters (D). Preoperative cylinder was -1.66 +/- 1.20 D. The residual sphere was +0.43 +/- 0.90 D three months and +0.21 +/- 0.90 D six months after surgery (P = .0001). The cylinder was -0.71 +/- 0.60 D and -0.67 +/- 0.60 D, respectively (P = .4). The UCVA was 0.75 +/- 0.2 and 0.81 +/- 0.2 (P = .0001) and the BSCVA was 0.94 +/- 0.1 and 1.01 +/- 0.1 (P = .0001), respectively. Those patients with a myopic defect (sphere or cylinder) three months postoperatively did not show any significant change in UCVA or refractive defect six months after surgery, while those with a hyperopic defect (sphere or cylinder) showed an improvement in UCVA and residual refraction six months postoperatively (P < .05). CONCLUSIONS: Our results suggest that retreatment after myopic LASEK with MMC may be performed three months after surgery when the residual refraction is myopic, but it seems wise to wait at least six months after surgery when the residual refraction is hyperopic. |
| | |
Authors:
|
Laura de Benito-Llopis; Miguel A Teus; José L Hernández-Verdejo |
Related Documents
:
|
7216626 - Effects of timolol on corneal sensitivity and tear production. 10964846 - Functional outcome and satisfaction after photorefractive keratectomy. part 1: developm... 2879296 - Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients under... 9820936 - Intraoperative versus postoperative suture adjustment after penetrating keratoplasty. 15545096 - Long pulsed dye laser treatment of facial wrinkles. 6846686 - Preliminary report on the jones, ellison, slocum (jes) repair for symptomatic anterior ... |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2008-09-06 |
Journal Detail:
|
Title: American journal of ophthalmology Volume: 147 ISSN: 1879-1891 ISO Abbreviation: Am. J. Ophthalmol. Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2008-12-22 Completed Date: 2009-01-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370500 Medline TA: Am J Ophthalmol Country: United States |
Other Details:
|
Languages: eng Pagination: 71-76.e2 Citation Subset: AIM; IM |
Affiliation:
|
Vissum Madrid, Madrid, Spain. lbenito@vissum.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Alkylating Agents / administration & dosage* Combined Modality Therapy Female Follow-Up Studies Humans Keratectomy, Subepithelial, Laser-Assisted / methods* Lasers, Excimer / therapeutic use* Male Middle Aged Mitomycin / administration & dosage* Myopia / physiopathology, therapy* Postoperative Period Prospective Studies Refraction, Ocular / physiology* Reoperation Time Factors Visual Acuity / physiology* |
| Chemical | |
Reg. No./Substance:
|
0/Alkylating Agents; 50-07-7/Mitomycin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predicting visual outcome after treatment of pituitary adenomas with optical coherence tomography.
Next Document: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month r...